维普中文期刊产品整合服务
14篇 您的检索式:作者名="Angels Serra"
    题名 作者 年代 出处 被引量
1Biometric and ICL-related risk factors associated to sub-optimal vaults in eyes implanted with implantable collamer lenses显示文摘Background:To identify biometric and implantable collamer lens(ICL)-related risk factors associated with suboptimal postoperative vault in eyes implanted with phakic ICL.Methods:This study reports a retrospective case series of the first operated eye in 360 patients implanted with myopic spherical or toric ICL.Preoperatively,white-to-white(WTW),central keratometry(Kc)and central corneal thickness(CCT)were measured using the Pentacam.Anterior-segment optical coherence tomography(AS-OCT,Visante)was applied preoperatively for measuring the horizontal anterior-chamber angle-to-angle distance(ATA),internal anterior chamber depth(ACD),crystalline lens rise(CLR),anterior-chamber angle(ACA)and postoperatively the vault.Eyes were divided into three vault groups:low(LVG:≤250μm),optimal(OVG:>250 and<1000μm)and high(HVG:≥1000μm).Multinomial logistic regression(MLR)was used to find the sub-optimal vault predictors.Results:MLR showed that CLR,ICL size minus the ATA(ICL size-ATA),age,ICL spherical equivalent(ICLSE)and ICL size as contributing factors for sub-optimal vaults(pseudo-R2=0.40).Increased CLR(OR:1.01,CI:1.00-1.01)and less myopic ICLSE(OR:1.22,CI:1.07-1.40)were risk factors for low vaults.Larger ICL size-ATA(OR:41.29,CI:10.57-161.22)and the 13.7mm ICL(OR:7.08,CI:3.16-15.89)were risk factors for high vaults,whereas less myopic ICLSE(OR:0.85,CI:0.76-0.95)and older age(OR:0.92,CI:0.88-0.98)were protective factors.Conclusion:High CLR and low ICLSE were the major risk factors in eyes presenting low vaults.In the opposite direction,ICL size-ATA was the major contributor for high vaults.This relationship was more critical in higher myopic ICLSE,younger eyes and when 13.7mm ICL were used.The findings show that factors influencing the vault have differentiated weight of influence depending on the type of vault(low,optimal or high).Santiago Cerpa Manito Angel Sánchez Trancón Oscar Torrado Sierra António Manuel Baptista Pedro Miguel Serra 2021Eye and Vision2021,8,1:5
2Optimal synthesis of regeneration systems subject to environmental constraints显示文摘Monica Carvalho Luis Maria Serra Miguel Angel 2011Energy2011,36,6:1
3Polylactones Influence of Various Metals Salts on the Optical Purity of Poly (L-lactide)显示文摘 SERRA ANGELS 1995Polymer Bulletin1995,14,:1
4The EXAMINATION (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction) Trial显示文摘Manel Sabaté Salvatore Brugaletta Angel Cequier Andrés I?iguez Antonio Serra Rosana Hernádez-Antolín Vicente Mainar Marco Valgimigli Maurizio Tespili Pieter den Heijer Armando Bethencourt Nicolás Vázquez Bianca Backx Patrick W. Serruys 2013JACC: Cardiovascular Interventions2013,,:1
5Incidence and risk factors for hepacellular carcinoma in 967 patients with cirrhosis显示文摘Juan Angel del Olmo Miguel Angel Serra Felicidad Rodriguez 1998J Cancer Res Clin Oncol1998,124,:1
6New aro- matic-aliphatic hyperbranched polyesters with vinylie end groups of different length as modifiers of epoxy/anhydride thermosets 显示文摘Adrian Tomuta Francesc Ferrando Angels Serra 2012Reac- tive & Functional Polymers2012,72,:1
7Novel epoxy-anhydride thermosets modified with a hyperbranched polyester as toughness enhancer. I. Kinetics study显示文摘Marjorie Flores Xavier Fernández-Francos Xavier Ramis Angels Serra 2012Thermochimica Acta2012,,:1
8Study on the chemicalmodification of epoxy/anhydride thermosets using a hydroxyl terminatedhyperbranched polymer显示文摘DavidFoix Yingfeng Yu Angels Serra 2009European Polymer Journal2009,45,5:1
9Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: a systematic review and meta-analysis显示文摘Matheus Roque Karinna Lattes Sandra Serra Ivan Solà Selmo Geber Ramón Carreras Miguel Angel Checa 2012Fertility and Sterility2012,,:1
10The EXAMINATION (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction) Trial显示文摘Manel Sabaté Salvatore Brugaletta Angel Cequier Andrés I?iguez Antonio Serra Rosana Hernádez-Antolín Vicente Mainar Marco Valgimigli Maurizio Tespili Pieter den Heijer Armando Bethencourt Nicolás Vázquez Bianca Backx Patrick W. Serruys 2013JACC: Cardiovascular Interventions2013,,:1
11Comparison of Newer-Generation Drug-Eluting Stents With Bare-Metal Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction显示文摘Manel Sabaté Lorenz R?ber Dik Heg Salvatore Brugaletta Henning Kelbaek Angel Cequier Miodrag Ostojic Andrés I?iguez David Tüller Antonio Serra Andreas Baumbach Clemens von Birgelen Rosana Hernandez-Antolin Marco Roffi Vicente Mainar Marco Valgimigli Patri 2013JACC: Cardiovascular Interventions2013,,:1
12Incidence and risk factors for hepacellular carcinoma in 967 patients with cirrhosis 显示文摘Juan Angel del Olmo Miguel Angel Serra Felicidad Rodriguez et al 1998J Cancer Res Clin Oncol1998,124,:1
13Biometric and ICL-related risk factors associated to sub-optimal vaults in eyes implanted with implantable collamer lenses显示文摘Background To identify biometric and implantable collamer lens(ICL)-related risk factors associated with sub-optimal postoperative vault in eyes implanted with phakic ICL.Methods This study reports a retrospective case series of the first operated eye in 360 patients implanted with myopic spherical or toric ICL.Preoperatively,white-to-white(WTW),central keratometry(Kc)and central corneal thickness(CCT)were measured using the Pentacam.Anterior-segment optical coherence tomography(AS-OCT,Visante)was applied preoperatively for measuring the horizontal anterior-chamber angle-to-angle distance(ATA),internal anterior chamber depth(ACD),crystalline lens rise(CLR),anterior-chamber angle(ACA)and postoperatively the vault.Eyes were divided into three vault groups:low(LVG:≤250μm),optimal(OVG:>250 and<1000μm)and high(HVG:≥1000μm).Multinomial logistic regression(MLR)was used to find the sub-optimal vault predictors.Results MLR showed that CLR,ICL size minus the ATA(ICL size-ATA),age,ICL spherical equivalent(ICLSE)and ICL size as contributing factors for sub-optimal vaults(pseudo-R2=0.40).Increased CLR(OR:1.01,CI:1.00–1.01)and less myopic ICLSE(OR:1.22,CI:1.07–1.40)were risk factors for low vaults.Larger ICL size-ATA(OR:41.29,CI:10.57–161.22)and the 13.7 mm ICL(OR:7.08,CI:3.16–15.89)were risk factors for high vaults,whereas less myopic ICLSE(OR:0.85,CI:0.76–0.95)and older age(OR:0.92,CI:0.88–0.98)were protective factors.Conclusion High CLR and low ICLSE were the major risk factors in eyes presenting low vaults.In the opposite direction,ICL size-ATA was the major contributor for high vaults.This relationship was more critical in higher myopic ICLSE,younger eyes and when 13.7 mm ICL were used.The findings show that factors influencing the vault have differentiated weight of influence depending on the type of vault(low,optimal or high).Santiago Cerpa Manito Angel Sánchez Trancón Oscar Torrado Sierra António Manuel Baptista Pedro Miguel Serra 2023Eye and Vision2023,9,5:0
14Effectiveness and safety of first-generation protease inhibitors in clinical practice:Hepatitis C virus patients with advanced fibrosis显示文摘AIM:To evaluates the effectiveness and safety of the first generation,NS3/4A protease inhibitors(PIs) in clinical practice against chronic C virus,especially in patients with advanced fibrosis. METHODS:Prospective study and non-experimental analysis of a multicentre cohort of 38 Spanish hospitals that includes patients with chronic hepatitis C genotype 1,treatment-na?ve(TN) or treatment-experienced(TE),who underwent triple therapy with the first generation NS3/4A protease inhibitors,boceprevir(BOC) and telaprevir(TVR),in combination with pegylated interferon and ribavirin. The patients were treatment in routine practice settings. Data on the study population and on adverse clinical and virologic effects were compiled during the treatment period and during follow up.RESULTS:One thousand and fifty seven patients were included,405(38%) were treated with BOC and 652(62%) with TVR. Of this total,30%(n = 319) were TN and the remaining were TE:28%(n = 298) relapsers,12%(n = 123) partial responders(PR),25%(n = 260) null-responders(NR) and for 5%(n = 57) with prior response unknown. The rate of sustained virologic response(SVR) by intention-to-treatment(ITT) was greater in those treated with TVR(65%) than in those treated with BOC(52%)(P < 0.0001),whereas by modified intention-to-treatment(m ITT) no were found significant differences. By degree of fibrosis,56% of patients were F4 and the highest SVR rates were recorded in the non-F4 patients,both TN and TE. In the analysis by groups,the TN patients treated with TVR by ITT showed a higher SVR(P = 0.005). However,by m ITT there were no significant differences between BOC and TVR. In the multivariate analysis by m ITT,the significant SVR factors were relapsers,IL28 B CC and non-F4; the type of treatment(BOC or TVR) was not significant. The lowest SVR values were presented by the F4-NR patients,treated with BOC(46%) or with TVR(45%). 28% of the patients interrupted the treatment,mainly by non-viral response(51%):this outcome was more frequent in the TE than in the TN patients(57% vs 40%,P = 0.01). With respect to severe haematological disorders,neutropaenia was more likely to affect the patients treated with BOC(33% vs 20%,P ≤ 0.0001),and thrombocytopaenia and anaemia,the F4 patients(P = 0.000,P = 0.025,respectively). CONCLUSION:In a real clinical practice setting with a high proportion of patients with advanced fibrosis,effectiveness of first-generation PIs was high except for NR patients,with similar SVR rates being achieved by BOC and TVR.Javier Salmeron Carmen Vinaixa Ruben Berenguer Juan Manuel Pascasio Juan Jose Sanchez Ruano Miguel angel Serra Ana Gila Moises Diago Manuel Romero-Gomez Jose Maria Navarro Milagros Testillano Conrado Fernandez Dolores Espinosa Isabel Carmona Jose Antonio Pons Francisco Jorquera Francisco Javier Rodriguez Ramon Perez Jose Luis Montero Rafael Granados Miguel Fernandez Ana Belen Martin Paloma Munoz de Rueda Rosa Quiles 2015World Journal of Gastroenterology2015,21,30:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费